while sialylated glycoforms were less. Both products exhibited the same glycan structures attached to Asn297 of heavy chain. As the N-glycan structures of both molecules were identical, and so far none of immunogenic sugar epitopes like alfa Gal–Gal and N-glycolyl sialic acid has been detected, differences in immunogenicity and safety between both Racotumomab were not expected.